Randall Pollard
About Randall Pollard
Randall E. Pollard is Chief Accounting Officer (principal accounting officer) of Harrow, Inc., appointed on August 21, 2025, with a start date of September 1, 2025; he reports to Andrew R. Boll (President & CFO) and leads accounting operations, financial reporting, internal controls, and SEC reporting processes . Pollard is a CPA with 20+ years in public-company reporting; he holds a B.S. in Accounting (Penn State) and an MBA (Fairleigh Dickinson) . He is an executive officer who signed Harrow’s Q3 2025 Form 10‑Q as principal accounting officer . For performance context, Harrow’s pay-versus-performance table shows total shareholder return rising to $388 (value of $100 initial investment) in 2024, with executive annual bonuses historically tied 100% to corporate metrics including revenue, adjusted EBITDA, specific product revenue, and stock price performance .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Cue Health, Inc. | Chief Accounting Officer | Apr 2022 – Jun 2024 | Senior accounting leadership; public company financial reporting oversight |
| Covis Pharmaceuticals, Inc. (private) | SVP Finance & Chief Accounting Officer | Nov 2020 – Apr 2022 | Led corporate accounting and finance at a private life sciences firm |
| Akorn (public pharma) | SVP, Finance & Chief Accounting Officer | Not disclosed | Senior finance/accounting leadership at a publicly traded pharmaceutical company |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Not disclosed | — | — | No external board or directorships disclosed in filings |
Fixed Compensation
| Component | Terms | Source |
|---|---|---|
| Base Salary | $400,000 annual | 8‑K appointment; Offer Letter Exhibit |
| Target Bonus % | 40% of salary; discretionary, based on targets agreed with CFO; employment on “Day of Payment” required | 8‑K; Offer Letter |
| Relocation | Up to $20,000; repayment if departure within one year | Offer Letter |
| Severance | After 12 months of service, if terminated without cause: 6 months of base compensation via normal payroll | Offer Letter |
Performance Compensation
| Incentive Type | Key Terms | Vesting/Triggers | Source |
|---|---|---|---|
| Stock Options | Option to purchase 30,000 Harrow shares, subject to equity plan; exercise price = FMV at grant; grant subject to Compensation Committee approval | 4-year vesting: 25% at 1-year anniversary (7,500 options), then remaining 22,500 options vest in equal quarterly installments (1,875/quarter) over next 12 quarters, contingent on continued service | Offer Letter |
| Annual Bonus | Target 40% of base salary; discretionary targets agreed with CFO | Must be employed on “Day of Payment”; specific metrics/weightings not disclosed | Offer Letter |
| Company bonus framework (context) | For 2024 executives, annual bonus based 100% on corporate metrics: revenue, adjusted EBITDA, certain product revenue, and stock price performance | Weighting and payout outcomes for Pollard not disclosed; framework indicative of pay-for-performance emphasis | DEF 14A |
Equity Ownership & Alignment
- Beneficial ownership: Not disclosed for Pollard in the 2025 proxy’s ownership table (covers executives and directors as of April 21, 2025), as his appointment occurred later; no Form 3/4 for Pollard was found in the documents queried here .
- Hedging/pledging policy: Directors and officers are prohibited from holding Harrow securities in margin accounts or pledging as collateral; short sales and most derivatives are prohibited; hedging/monetization transactions are strongly discouraged and require compliance approval .
- Stock ownership guidelines: Not disclosed in the filings reviewed .
- Vested vs. unvested: 30,000 options are unvested at grant; first vesting tranche after one year, then quarterly vest thereafter per schedule .
Employment Terms
| Term | Details | Source |
|---|---|---|
| Start Date & Role | Appointed Aug 21, 2025; start Sep 1, 2025; Chief Accounting Officer (principal accounting officer) reporting to President & CFO | |
| At‑Will Employment | Employment is at‑will; Harrow may modify duties/reporting to meet business needs | |
| Policies & Agreements | Required to sign Confidentiality, Arbitration, and Proprietary Information & Inventions Assignment Agreements; subject to Code of Business Conduct and Ethics and Insider Trading Policy | |
| Indemnification & D&O | Entitled to indemnification per company policy and covered under applicable D&O insurance | |
| Non‑compete/Non‑solicit | Not disclosed in Offer Letter/8‑K reviewed | |
| Change‑of‑Control (Equity) | Under the equity plan, in a “Covered Transaction,” the Compensation Committee may provide for accelerated vesting/cash‑out/assumption of awards; director awards accelerate; employee award acceleration at Committee discretion |
Investment Implications
- Near-term selling pressure appears limited until the one-year cliff (7,500 options) vests; thereafter, a steady quarterly vesting cadence (1,875 options per quarter) could create incremental liquidity events, subject to blackout windows and insider trading policy .
- Bonus design (targets with CFO; employment on pay date required) and company’s historical emphasis on revenue/adjusted EBITDA/stock price performance suggest alignment to operating and shareholder outcomes, though Pollard’s specific metrics/weightings are undisclosed .
- Governance mitigants: prohibition on pledging/margin and strict hedging discouragement reduce alignment risk; plan’s “no repricing” provision protects shareholders from underwater option repricing .
- Retention risk: severance only after 12 months and limited to 6 months’ base compensation indicates moderate retention incentives; absence of rich change‑of‑control economics specific to Pollard reduces transaction‑driven windfalls .